Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer (FRA:BAYN) in a research report report published on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
Other equities research analysts have also recently issued research reports about the company. Berenberg Bank set a €67.00 ($77.91) target price on Bayer and gave the company a neutral rating in a research note on Wednesday, July 31st. Barclays set a €85.00 ($98.84) target price on Bayer and gave the company a buy rating in a research note on Wednesday, October 9th. HSBC set a €63.00 ($73.26) target price on Bayer and gave the company a neutral rating in a research note on Wednesday, August 7th. DZ Bank restated a neutral rating on shares of Bayer in a research note on Monday. Finally, UBS Group set a €110.00 ($127.91) target price on Bayer and gave the company a buy rating in a research note on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of €79.90 ($92.91).
FRA BAYN opened at €67.32 ($78.28) on Tuesday. The stock’s 50 day moving average price is €65.63 and its two-hundred day moving average price is €60.62. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Basic Economics
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.